Pipeline
A pipeline of neuroprotectants for multiple indications, Avilex’ lead compound, AVLX-144, is entering Phase 2 clinical trials, and a range of new preclinical assets are being developed
Compound(s)
Lead Optimization
Non-Clinical
Regulatory Toxicology
Phase I
Phase II
Phase III
AVLX-144
Carefully optimized, unique structure
Extensively characterized in stroke in vivo models
Completed full toxicology package
Completes clinical trial Phase I
2nd GenerationPSD-95 Inhibitors
New potent inhibitors with unique properties
In vivo characterization ongoing
PSD-95 PET TracerClinical Biomarker Studies
Highly promising PSD-95 biomarker developed
In vivo characterization ongoing
Cyclic PeptidePSD-95 Inhibitors
Novel, potent cyclic peptide inihibtors developed
AVLX-144
Lead Optimization
Carefully optimized, unique structure
Non-Clinical
Extensively characterized in stroke in vivo models
Regulatory Toxicology
Completed full toxicology package
Phase I
Completes clinical trial Phase I
Phase II
Phase III
2nd Generation
PSD-95 Inhibitors
Lead Optimization
New potent inhibitors with unique properties
Non-Clinical
In vivo characterization ongoing
Regulatory Toxicology
Phase I
Phase II
Phase III
PSD-95 PET Tracer
Clinical Biomarker Studies
Lead Optimization
Highly promising PSD-95 biomarker developed
Non-Clinical
Extensively characterized in stroke in vivo models
Regulatory Toxicology
Phase I
Phase II
Phase III
Cyclic Peptide
PSD-95 Inhibitors